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ABSTRACT 
 
 
Measles is a vaccine-preventable disease. Implementation of global vaccination 
programmes has resulted in a dramatic decrease in measles-related deaths, from 2.6 million 
in 1980 to 164 000 in 2008. To support the global measles elimination goal, laboratories 
provide case-based surveillance which includes both serological diagnosis and viral 
characterisation using molecular platforms.  
 
In this study, conventional hemi-nested amplification methods were developed to detect the 
nucleoprotein- and haemagglutinin-genes of measles virus, in specimens collected for rash-
surveillance programmes in Africa. Viral characterisation involved amplicon sequencing and 
phylogenetic analyses of 1402 PCR-positive specimens (2655 specimens tested, 52.8% 
PCR-positive) with sequence submission to global databases. Only imported strains of 
genotypes B2, B3, D2, D4 and D8, have been detected in South Africa since 2002, 
demonstrating the successful interruption of transmission of endemic strains. Genotypic 
analyses of specimens from African countries provided information relating to strain origins, 
as well as temporal and spatial data relevant to the molecular epidemiology of measles in 
Southern Africa.  
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